Dr. Isaac Eliaz

Eliaz Therapeutics, Inc. (ETI) was established to advance the development of an innovative medical device that removes galectin-3 from the bloodstream using therapeutic apheresis. Galectin-3 plays a critical role in inflammation and fibrosis, making it a key target for addressing life-threatening conditions such as sepsis. Sepsis is a severe, life-threatening response to infection that leads to widespread inflammation, organ failure, and often death. Despite advancements in critical care, sepsis remains a leading cause of mortality, with over 2 million cases annually in the U.S. and more than 350,000 deaths. Galectin-3 has been identified as a major contributor to sepsis progression, driving excessive inflammation and immune system dysfunction. ETI’s breakthrough technology is designed to selectively target and remove galectin-3, offering a novel and potentially life-saving treatment option for sepsis patients. By reducing galectin-3 levels, the device aims to: * Mitigate excessive inflammation and prevent multi-organ failure * Improve patient outcomes and reduce mortality rates * Lower healthcare costs associated with prolonged ICU stays and long-term complications Beyond sepsis, ETI’s platform technology holds promise for other galectin-3-driven conditions, including acute kidney injury (AKI), cardiovascular disease, and fibrotic disorders. The company has secured a strategic collaboration with Terumo BCT and continues to advance toward FDA approval with support from leading experts and clinical partners. With a growing body of evidence and a strong commitment to innovation, ETI is poised to revolutionize the treatment of sepsis and related inflammatory conditions, providing new hope for patients and healthcare providers worldwide.

Amitabha Medical Clinic is an integrative medical center with a focus on cancer and difficult to treat chronic illnesses and infections. integrating Western medicine and modern and up to date research with ancient wisdom, Amitabha clinic provides individualized care that addresses the person as a whole, utilizing mind-body medicine together with cutting edge therapeutic approaches such as therapeutic apheresis.

EcoNugenics, founded in 1995, is a research-driven dietary supplement company known for its high-value products. Since late 2015, I have not been involved in the day-to-day management of the company. Under the leadership of Anat Stern, EcoNugenics thrived and was successfully acquired in 2023.

(Formerly, Our Kids’ Sake), a non-profit organization that supports homeless children and advances mind-body medicine